Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;4(1):11-23.
doi: 10.2217/cns.14.49.

Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases

Nemica Thavarajah  1 , Saurabh Ray, Gillian Bedard, Liying Zhang, David Cella, Erin Wong, Cyril Danjoux, May Tsao, Elizabeth Barnes, Arjun Sahgal, Hany Soliman, Natalie Pulenzas, Breanne Lechner, Edward Chow
Affiliations

Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases

Nemica Thavarajah et al. CNS Oncol. 2015.

Abstract

Objective: To test the reliability, clinical and psychometric validity of the Brain Symptom and Impact Questionnaire (BASIQ) in patients with brain metastases.

Methods: Brain metastases patients were interviewed using the BASIQ, Functional Assessment of Cancer-Brain (FACT-Br) and FACT-General (FACT-G) at baseline, with a follow-up assessment at 1 month.

Results: Forty patients had complete one data and the median age was 64 years. Patients with higher KPS, ECOG of 2, primary breast cancer, or >3 brain metastases, scored higher on the symptom scale of the BASIQ. All subscales showed no significant change in patient symptoms from baseline to follow-up.

Conclusion: This study supports that the reliability, clinical and psychometric validity of BASIQ to be used in brain metastases patients.

Keywords: BASIQ; brain metastases; field-testing; psychometric validation; quality of life; questionnaire.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Mean BASIQ item scores at baseline and 1-month follow-up assessment (n = 40 patients).
<b>Figure 2.</b>
Figure 2.. Mean FACT-G and FACT-Br subscale scores for the past 24 h and past 7 days at baseline and 1-month follow-up (n = 40 patients).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Serres S, Soto MS, Hamilton A, et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc. Natl Acad. Sci. USA. 2012;109(17):6674–6679. - PMC - PubMed
    1. Doyle M, Bradley NM, Li K, et al. Quality of life in patients with brain metastases treated with a palliative course of whole-brain radiotherapy. J. Palliat. Med. 2007;10(2):367–374. - PubMed
    1. Thomas SS, Dunbar EM. Modern multidisciplinary management of brain metastases. Curr. Oncol. Rep. 2010;12(1):34–40. - PubMed

    2. • Comprehensive review of current treatment options available for patients with brain metastases.

    1. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884–898. - PubMed
    1. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007;60(2):277–283. - PubMed

LinkOut - more resources